1. Home
  2. Stock quotes
  3. Assembly Biosciences
  4. Financial Statements
  5. Balance Sheet
Assembly Biosciences logo
Assembly Biosciences ASMB
$ 28.94 1.69%

Annual report 2025
added 03-19-2026

report update icon

Assembly Biosciences Balance Sheet 2011-2026 | ASMB

Annual Balance Sheet Assembly Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

 -55.8 M -35.3 M -17.5 M -49 M -39.2 M -49.3 M -34.5 M -41.5 M -82 M -28.6 M -27.1 M -29.1 M -27.1 M -20.5 M -37 M

Long Term Debt

 2.06 M 2.63 M 1.12 M 101 K 3.32 M - - - - - - - - - -

Long Term Debt Current

 569 K 461 K 1.22 M 3.36 M 3.15 M 3.4 M 3.19 M - - - - - - - -

Total Non Current Liabilities

 - - - - - 18.2 M 42.2 M 38.9 M 42.7 M 11.1 M 11.6 M 11.6 M - - -

Total Current Liabilities

 48.8 M 47.8 M 39.2 M 16.3 M 16.1 M 24.4 M 24.4 M 18.5 M 13.5 M 7.12 M 3.4 M 1.05 M 2.64 M - 2.51 M

Total Liabilities

 50.8 M 85.8 M 95.7 M 19.1 M 22.1 M 42.7 M 66.7 M 57.4 M 56.2 M 18.2 M 15 M 12.7 M 2.64 M 2.75 M 2.51 M

Deferred Revenue

 36.9 M 37.6 M 30.9 M - - 8.99 M 6.41 M 5.1 M 5.23 M - - - - - -

Retained Earnings

 -832 M -826 M -786 M -725 M -631 M -502 M -439 M -342 M -251 M -208 M -164 M -136 M -112 M -92.3 M -67.5 M

Total Assets

 258 M 119 M 137 M 102 M 191 M 283 M 340 M 268 M 169 M 98.1 M 134 M 71.2 M 27.1 M 20.6 M 37 M

Cash and Cash Equivalents

 58.4 M 38.3 M 19.8 M 52.4 M 45.6 M 59.4 M 46.7 M 41.5 M 82 M 28.6 M 27.1 M 29.1 M 27.1 M 20.5 M 37 M

Book Value

 207 M 33.4 M 41.1 M 82.7 M 169 M 241 M 273 M 211 M 113 M 79.9 M 119 M 58.6 M 24.5 M 17.8 M 34.5 M

Total Shareholders Equity

 207 M 33.4 M 41.1 M 82.7 M 169 M 241 M 273 M 211 M 113 M 79.9 M 119 M 58.6 M 24.5 M 17.8 M 34.5 M

All numbers in USD currency

Quarterly Balance Sheet Assembly Biosciences

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

 2.21 M 2.35 M 2.49 M 2.63 M 113 K 451 K 791 K 1.12 M 50 K 64 K 80 K 101 K 918 K 1.77 M 2.5 M 3.32 M 4.14 M 4.91 M 5.64 M 6.72 M 6.72 M 6.72 M 6.72 M 9.08 M 9.08 M 9.08 M 9.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

 - - - - - - - - - - - - - - - - - - - - - - - - - - - 38.9 M 38.9 M 40.2 M 41.5 M 42.7 M 42.7 M 42.7 M 42.7 M 11.1 M 11.1 M 11.1 M 11.1 M 11.6 M 11.6 M 11.6 M 11.6 M 11.6 M 11.6 M 11.6 M - - - - - - - - - - - - -

Total Liabilities

 57.3 M 62.7 M 71.9 M 85.8 M 74.3 M 80.6 M 87.3 M 95.7 M 9.92 M 11.6 M 12.8 M 19.1 M 19.1 M 19.5 M 15.9 M 22.1 M 24.3 M 30.3 M 31.7 M 42.7 M 42.7 M 42.7 M 42.7 M 66.7 M 66.7 M 66.7 M 66.7 M 57.4 M 57.4 M 57.4 M 57.4 M 56.2 M 56.2 M 56.2 M 56.2 M 18.2 M 18.2 M 18.2 M 18.2 M 15 M 15 M 15 M 15 M 12.7 M 12.7 M 12.7 M 12.7 M 2.64 M 2.64 M 2.64 M 2.64 M 2.75 M 2.75 M 2.75 M 2.75 M 2.51 M 1.18 M 2.09 M -

Deferred Revenue

 42.4 M 40.9 M 40.8 M 37.6 M 32.6 M 33.1 M 32.8 M 30.9 M - - - - - - - - - - - - - - 6.72 M 6.41 M 6.41 M 6.08 M 9.93 M 5.1 M 5.11 M 5.51 M 5.1 M 5.23 M 5.23 M 5.23 M 5.23 M - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

 -854 M -845 M -835 M -826 M -816 M -806 M -795 M -786 M -775 M -760 M -743 M -725 M -702 M -679 M -655 M -631 M -571 M -552 M -529 M -502 M -502 M -502 M -502 M -439 M -439 M -439 M -439 M -342 M -342 M -342 M -342 M -251 M -251 M -251 M -251 M -208 M -208 M -208 M -208 M -164 M -164 M -164 M -164 M -136 M -136 M -136 M -136 M -112 M -112 M - - - - - - - - - -

Total Assets

 240 M 80.8 M 99 M 119 M 100 M 115 M 120 M 137 M 51.6 M 66.6 M 83.1 M 102 M 122 M 143 M 163 M 191 M 249 M 262 M 279 M 283 M 283 M 283 M 283 M 340 M 340 M 340 M 340 M 268 M 268 M 268 M 268 M 169 M 169 M 169 M 169 M 98.1 M 98.1 M 98.1 M 98.1 M 134 M 134 M 134 M 134 M 71.2 M 71.2 M 71.2 M 71.2 M 27.1 M 27.1 M 27.1 M 27.1 M 20.6 M 20.6 M 20.6 M 20.6 M 37 M 37 M 37 M 37 M

Cash and Cash Equivalents

 22.5 M 24 M 23.4 M 38.3 M 28.5 M 19.2 M 18.7 M 19.8 M 26.7 M 21.6 M 43.5 M 52.4 M 54.7 M 43.1 M 51.2 M 45.6 M 70.8 M 59.5 M 78.3 M 59.4 M 59.4 M 59.4 M 59.4 M 46.7 M 46.7 M 46.7 M 46.7 M 41.5 M 41.5 M 41.5 M 41.5 M 82 M 82 M 82 M 82 M 28.6 M 28.6 M 28.6 M 28.6 M 27.1 M 27.1 M 27.1 M 27.1 M 29.1 M 29.1 M 29.1 M 29.1 M 27.1 M 27.1 M 27.1 M 27.1 M 20.5 M 20.5 M 20.5 M 20.5 M 37 M 37 M 37 M 37 M

Book Value

 183 M 18.1 M 27.1 M 33.4 M 26 M 34.7 M 32.6 M 41.1 M 41.7 M 54.9 M 70.3 M 82.7 M 102 M 124 M 147 M 169 M 225 M 232 M 247 M 241 M 241 M 241 M 241 M 273 M 273 M 273 M 273 M 211 M 211 M 211 M 211 M 113 M 113 M 113 M 113 M 79.9 M 79.9 M 79.9 M 79.9 M 119 M 119 M 119 M 119 M 58.6 M 58.6 M 58.6 M 58.6 M 24.5 M 24.5 M 24.5 M 24.5 M 17.8 M 17.8 M 17.8 M 17.8 M 34.5 M 35.9 M 35 M 37 M

Total Shareholders Equity

 183 M 18.1 M 27.1 M 33.4 M 26 M 34.7 M 32.6 M 41.1 M 41.7 M 54.9 M 70.3 M 82.7 M 102 M 124 M 147 M 169 M 225 M 232 M 247 M 241 M 241 M 241 M 241 M 273 M 273 M 273 M 273 M 211 M 211 M 211 M 211 M 113 M 113 M 113 M 113 M 79.9 M 79.9 M 79.9 M 79.9 M 119 M 119 M 119 M 119 M 58.6 M 58.6 M 58.6 M 58.6 M 24.5 M 24.5 M 24.5 M 24.5 M 17.8 M 17.8 M 17.8 M 17.8 M 34.5 M 34.5 M 34.5 M 34.5 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Assembly Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
 		- 2.43 % $ 254 M germanyGermany
Grifols, S.A. Grifols, S.A.
GRFS
 		$ 7.71 1.65 % $ 6.83 B spainSpain
Altimmune Altimmune
ALT
 		$ 3.5 4.64 % $ 308 M usaUSA
I-Mab I-Mab
IMAB
 		- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
 		- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
 		- 2.54 % $ 160 B franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
 		$ 221.52 -0.16 % $ 5 B danmarkDanmark
Biophytis SA Biophytis SA
BPTS
 		- -13.47 % $ 169 M franceFrance
Heron Therapeutics Heron Therapeutics
HRTX
 		$ 0.8 2.5 % $ 133 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
 		- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
 		- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		- - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
 		- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
 		- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
 		- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
 		- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
 		- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
 		- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
 		- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
 		- - - russiaRussia
Avenue Therapeutics Avenue Therapeutics
ATXI
 		- -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
 		- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
 		- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
 		- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
 		- - $ 7.46 M israelIsrael
Immunovant Immunovant
IMVT
 		$ 24.27 5.61 % $ 3.68 B usaUSA
Incyte Corporation Incyte Corporation
INCY
 		$ 90.82 0.04 % $ 17.7 B usaUSA
Atreca Atreca
BCEL
 		- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
 		- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
 		- 0.49 % $ 251 B cayman-islandsCayman-islands
InMed Pharmaceuticals InMed Pharmaceuticals
INM
 		$ 0.79 -3.52 % $ 1.93 M canadaCanada
INmune Bio INmune Bio
INMB
 		$ 1.23 5.13 % $ 22.1 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
 		$ 1.57 -0.95 % $ 34.8 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
 		$ 1.34 14.26 % $ 235 M franceFrance
Calithera Biosciences Calithera Biosciences
CALA
 		- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
 		- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
 		- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
 		- -74.18 % $ 955 K usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
 		- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
 		- -7.23 % $ 13 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
 		$ 6.09 5.36 % $ 138 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
 		- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
 		- - $ 867 M germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
 		$ 2.13 1.91 % $ 199 M israelIsrael
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
 		$ 16.93 -0.41 % $ 841 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
 		- - $ 3.67 B usaUSA
CorMedix CorMedix
CRMD
 		$ 6.35 1.6 % $ 457 K usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
 		$ 4.33 2.12 % $ 719 M canadaCanada
Kamada Ltd. Kamada Ltd.
KMDA
 		$ 8.33 0.97 % $ 260 M israelIsrael
Akouos Akouos
AKUS
 		- 0.23 % $ 488 M usaUSA